Anticholinergic drugs may lead to mild mental impairment in elderly

Anticholinergic drugs may lead to mild cognitive (mental) impairment in elderly people, finds a study published online by the British Medical Journal.

These drugs are commonly used in elderly patients to treat illnesses such as irritable bowel syndrome, urinary incontinence, and Parkinson's disease, so it is important that doctors are aware of this effect, say the researchers.

They interviewed 372 elderly people without dementia about current and past illnesses and drug use. Cognitive performance was assessed and participants were monitored for up to eight years.

About 10% of the people in the sample took anticholinergic drugs over an extended period. Drug users showed poorer cognitive performance compared with non-users and 80% met the criteria for mild cognitive impairment compared with 35% of non-users. However, drug users were not at increased risk of developing dementia.

Even after taking account of other known risk factors for cognitive impairment, anticholinergic drugs remained the most highly significant predictor of this condition, say the authors.

Given the aim of identifying mild cognitive impairment is the early treatment of dementia, people with mild cognitive impairment due to anticholinergic drugs could be in the absurd situation of receiving pro-cholinergic drugs to counteract the effects of anticholinergic agents, say the authors.

They suggest doctors assess current use of anticholinergic drugs in elderly people with mild cognitive impairment before considering treatment for dementia.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Small brain-penetrating molecule offers hope for treating aggressive brain tumors